King's College London

Research portal

An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors

Research output: Contribution to journalArticlepeer-review

Hend Mohamed Abdel-Bar, Adam A. Walters, Yau Lim, Nadia Rouatbi, Yue Qin, Fatemeh Gheidari, Shunping Han, Rihab Osman, Julie Tzu Wen Wang, Khuloud T. Al-Jamal

Original languageEnglish
Pages (from-to)8738-8754
Number of pages17
JournalTheranostics
Volume11
Issue number18
DOIs
Published2021

Bibliographical note

Funding Information: H.A. is a recipient of Newton Musharafa Fellowship. This project has received funding from the Brain Tumour Charity (GN-000398), Institutional Link-British Council (IL4337313), Wellcome Trust (WT103913) and Cancer Research UK King’s Health Partners Centre at King’s College London. We thank the IQPath facility (Francesca Launchbury and Daniel Gharai) at University College London for excellent histological assistance. Publisher Copyright: © The author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an ‘eat me’ signal. This manuscript describes the development of a stable nucleic acid-lipid particles (SNALPs) formulation for the simultaneous delivery of ICD inducing drug (Dox) with small interfering RNA (siRNA) knocking down CD47 (siCD47), the dominant ‘don’t eat me’ marker, for synergistic enhancement of ICD. Methods: SNALPs loaded with Dox or siCD47 either mono or combinatory platforms were prepared by ethanol injection method. The proposed systems were characterized for particle size, surface charge, entrapment efficiency and in vitro drug release. The ability of the SNALPs to preserve the siRNA integrity in presence of serum and RNAse were assessed over 48 h. The in vitro cellular uptake and gene silencing of the prepared SNALPs was assessed in CT26 cells. The immunological responses of the SNALPs were defined in vitro in terms of surface calreticulin expression and macrophage-mediated phagocytosis induction. In vivo therapeutic studies were performed in CT26 bearing mice where the therapeutic outcomes were expressed as tumor volume, expression of CD4 and CD8 as well as in vivo silencing. Results: The optimized SNALPs had a particle size 122 ±6 nm and an entrapment efficiency > 65% for both siRNA and Dox with improved serum stability. SNALPs were able to improve siRNA and Dox uptake in CT26 cells with enhanced cytotoxicity. siCD47 SNALPs were able to knockdown CD47 by approximately 70% with no interference from the presence of Dox. The siCD47 and Dox combination SNALPs were able to induce surface calreticulin expression leading to a synergistic effect on macrophage-mediated phagocytosis of treated cells. In a tumor challenge model, 50% of mice receiving siCD47 and Dox containing SNALPs were able to clear the tumor, while the remaining animals showed significantly lower tumor burden as compared to either monotreatment. Conclusion: Therefore, the combination of siCD47 and Dox in a particulate system showed potent anti-tumor activity which merits further investigation in future clinical studies.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454